Please login to the form below

cardiovascular drug

This page shows the latest cardiovascular drug news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Lundbeck gets new leader, Recordati sold, GSK-backed firm prepares for market

Last year the Italian firm paid $300m to purchase AstraZeneca’s European rights to cardiovascular drug Seloken and related combination Logimax. ... Its PRINT technology is a particle engineering platform which allows precise production of uniform drug

Latest news

J&J says real-world data finds no amputation risk for Invokana

The changes came after the results of the CANVAS trial suggested that the drug was able to reduce cardiovascular outcomes in diabetic patients, like competitors including Eli Lilly and Boehringer ... Florida over the weekend – that it says backs up the
AZ taps Ionis for another drug, this time in NASH

It’s the third time AZ has taken up an option on an Ionis drug under a 2015 alliance in the area of cardiovascular, metabolic and kidney disease, after earlier deals ... for cardiovascular drug AZD8233 and kidney disease candidate AZD2373.
AZ finally gets EU nod for Veltassa rival Lokelma

Drug therapy is often modified or discontinued in HF patients as a result, but this can increase the risk of death. ... Björk, who heads up AZ’s cardiovascular, renal and metabolism drug development.
Sanofi, Regeneron offer price cut for cholesterol drug Praluent

be acceptable for the drug – depending on the patient’s level of risk. ... Amgen - which has been locked in litigation with Sanofi and Regeneron over PCSK9 patent rights - reported positive cardiovascular outcomes data for its drug last year when it
J&J seeks US OK to add CV claim to Invokana label

Johnson &Johnson has moved swiftly ahead with a filing for its diabetes drug Invokana that would include a claim that it can reduce major adverse cardiovascular events (MACE). ... s drug has the most to gain from cardiovascular labelling, threatening

More from news
Approximately 2 fully matching, plus 87 partially matching documents found.

Latest Intelligence

Perfecting the pharmaceutical pipeline with AI

For example, a drug being used for cardiovascular disease might be found to have useful qualities for neurological diseases. ... We’re already seeing evidence of how AI can positively impact drug discovery.
Going the distance

Looking to the second half of this year and Sanofi is aiming for a Q3 launch for its new PCSK9 cardiovascular disease management drug Praluent (alirocumab), which comes from its collaboration ... centric means that you need to think about your patients
Interview: Peter Meeus, Novo Nordisk

Several obstacles stand in the way of the uptake of Tresiba in Europe, including the decision from the US FDA to request more data from Novo Nordisk regarding the drug's ... cardiovascular safety before it can be approved.
Pharma deals during October 2012

In return for granting Merck a global exclusive licence to its cardiovascular drug candidates, Theravance will receive $153m in R&D funding and milestone payments, including a $5m upfront payment and ... 101. Advinus / Takeda. 3 yr discovery,
Pharma deals during July 2012

These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein ... 168. Vestiq / BioAlliance (a). Licence

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

Sanifit appoints Alexander Gold chief medical officer

Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others. ... A cardiologist with over 16 years experience of drug
Senior AstraZeneca exec jumps ship to small biotech

AstraZeneca's chief executive, Pascal Soriot, will take over the job of late-stage drug development on an interim basis, according to news reports. ... Meanwhile Elisabeth Björk, an associate professor of medicine at Uppsala university and leads
Milestone names chief medical officer

Cardiovascular specialist Milestone Pharmaceuticals has appointed experienced pharma researcher Dr Francis Plat as its new chief medical officer. ... Milestone's CEO Philippe Douville said: "Dr Plat is the perfect candidate for our development program
Jonathan Fox leaves AstraZeneca for MyoKardia

He also served for four years as the industry representative to the FDA's Cardiovascular and renal Drug Products Advisory Committee. ... By translating the groundbreaking science of the founding investigators into effective, disease modifying treatments,

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

Packer Forbes News November 2015

A graduate from the University of Bath, Lydia’ s study areas included Cardiovascular Pharmacology, Regenerative Medicine, Drug Targets in the Immune System with her dissertation focusing on the possibility of a

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.